GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
Pre-market 08:10:15 am | |||
| 67.29 USD | -0.90% |
|
67.45 | +0.24% |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 15 M€ | -1.62% | - | |
| 0.08% | 105 M€ | +3.88% | - | |
| 0.06% | 11 M€ | +2.67% | - | |
| 0.06% | 6 M€ | +3.89% | ||
| 0.05% | 17 M€ | +3.42% | - | |
| 0.04% | 54 M€ | +0.94% | - | |
| 0.03% | 23 M€ | +15.20% | - | |
| 0.03% | 234 M€ | +7.12% | - | |
| 0.03% | 8 M€ | +0.96% | - | |
| 0.02% | 6 M€ | -4.26% | - | |
| 0.01% | 34 M€ | +4.77% | - | |
| 7.69% | 129 M€ | +8.51% | - | |
| 11.65% | 28 M€ | +11.90% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.29
USD
Average target price
82.93
USD
Spread / Average Target
+23.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.94% | 83.83B | |
| +37.78% | 723B | |
| +31.39% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.00% | 244B | |
| +9.61% | 210B | |
| -4.99% | 208B | |
| +9.32% | 169B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.